Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 plus pembrolizumab versus pembrolizumab plus placebo in previously treated advanced or metastatic non-small cell lung cancer
2014-005614-29Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing CC-486 plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoint: Progression-free survival. Started Jul 2015; status: completed.
02
Drugs
azacitidinepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005614-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005614-29.